Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy
Status:
Recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label, adaptive, two arm, multicentre, Phase II trial comparing a
neoadjuvant chemotherapy with PDL1-inhibition (Atezolizumab) and Atezolizumab two-week window
to chemotherapy with PDL1-inhibition (Atezolizumab) and identify biomarkers predicting
(early) response to or resistance against Atezolizumab (alone and with CTX) allowing patients
stratification in future clinical trials
Phase:
Phase 2
Details
Lead Sponsor:
Palleos Healthcare GmbH
Collaborators:
Phaon Scientific GmbH Roche Pharma AG University Hospital Erlangen University Hospital, Essen